From GlobeNewswire: 2025-04-03 18:18:00

Annexon, Inc. presents Phase 3 data for ANX005 at AAN Annual Meeting, showcasing rapid and lasting benefits for GBS patients. An educational symposium highlights the role of the classical complement pathway in advancing GBS care. The “Move GBS Forward” campaign raises awareness of the physical and mental impact of GBS. GBS affects 150,000 worldwide annually with no FDA-approved treatments. ANX005 is a monoclonal antibody targeting C1q to improve recovery in GBS. Annexon Biosciences is leading the charge in developing innovative therapies for neuroinflammatory diseases.



Read more at GlobeNewswire: Annexon Highlights Leadership in Advancing Clinical